Kite, the Santa Monica, California-based cell therapy subsidiary of Gilead, has entered a definitive agreement to pay $350 ...

Fort Worth’s oldest African American Baptist church, which was recently put on a list of Most Endangered Places in the city, ...

CVS Health, one of the nation’s largest pharmacy benefit managers, has declined to cover Gilead’s newly FDA-approved HIV ...

BeOne Medicines entered a deal worth up to $950 million with Royalty Pharma selling its rights to global sales royalties of ...

At the International AIDS Society meeting this year, a young woman from South Africa spoke. She is the first Black woman from ...

The Asia Police Station in southern Manchester hosted its annual non-residential summer camp from August 11–16, with more ...

Renaissance Technologies’ Q2 2025 13F portfolio grew to $75B. Check out the significant stake increases and major reductions ...

Imdelltra is a first-in-class immunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) marketed by Amgen Royalty ...

Orman also has spotted some stock-market winners. On CNBC's "Fast Money" in late October 2023, she recommended Palantir Technologies (PLTR), Microsoft (MSFT), Amazon.com (AMZN), Shopify (SHOP) and ...

Surrogate endpoints increasingly are used for cancer drug approvals, but it’s not clear if these endpoints correlate with clinical benefit.

South Africa is among the first countries in line to receive doses of lenacapavir, the six-monthly injection for HIV prevention. According to national health department projections, the country could ...

CVS Health, one of the nation’s largest pharmacy benefit manager companies that play a lead role in deciding which drugs are ...